Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 5/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NPR1 | P16066 | 2/20 | 0.34 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.34 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25558883 | 0.91 | TACR3 (0.38) | DHODHMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL25199410 | 0.81 | PDE10A (0.39) | PDE10A | |
| SCHEMBL30367800 | 0.81 | PDE10A (0.39) | PDE10A | |
| SCHEMBL23887709 | 0.81 | PDE10A (0.39) | PDE10A | |
| SCHEMBL23906427 | 0.76 | MAPT (0.42) | DHODHMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL25193488 | 0.76 | MAPT (0.42) | DHODHMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL30450040 | 0.76 | MAPT (0.42) | DHODHMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL25193490 | 0.76 | MAPT (0.42) | DHODHMAPTALDH1A1HPGDHSD17B10 | |
| SCHEMBL25544347 | 0.74 | GRM2 (0.38) | DHODHMAPTALDH1A1CTNNB1TCF7L2 | |
| SCHEMBL25558851 | 0.74 | DPP4 (0.40) | DHODHTACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | DHODH 379/4885MAPT 2172/4885ALDH1A1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.